Please login to the form below

Not currently logged in
Email:
Password:

Sanofi Pasteur begins dengue vaccine study

Sanofi Pasteur, the vaccines division of sanofi-aventis has announced it is to begin a paediatric clinical study to test the efficacy of its tetravalent vaccine for dengue fever

Sanofi Pasteur, the vaccines division of sanofi-aventis has announced it is to begin a paediatric clinical study to test the efficacy of its tetravalent vaccine for dengue fever.

The study will be carried out in Thailand in collaboration with Mahidol University of Thailand, the Ministry of Public Health, and the Paediatric Dengue Vaccine Initiative. The programme follows guidelines from the Initiative for Vaccine Research (IVR) led by the World Health Organisation (WHO).

"Large scale paediatric studies are instrumental for the development of a safe and efficacious dengue vaccine to protect against a disease that primarily affects children," said Dr Pratap Singhasivanon, dean of the faculty of tropical medicine, Mahidol University. "We are happy to contribute to an important milestone with the actual start of an efficacy study in Ratchaburi."

Dengue fever is the most widespread tropical disease after malaria. Carried by mosquitoes, the disease is a threat to almost half of the world's population.

18th February 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics